TriClip Device May Be Safe and Effective at Reducing Tricuspid Regurgitation
The TriClip device may be safe and effective for lowering tricuspid regurgitation by 1 grade or more.
Valvular Heart Disease
VALVULAR HEART DISEASE
Latest News
Factors Associated With Increased Risk for AVR, Death in Aortic Stenosis
Atrial fibrillation, left ventricular ejection fraction (LVEF), abnormal right ventricular function, and ventricular hypertrophy were found to be associated with a greater risk for aortic valve replacement (AVR), death, or hospitalization for heart failure in patients with moderate aortic stenosis, according to a study published in The American Journal of Cardiology. In this retrospective single-center study,…
Lipid-Lowering Therapy May Reduce Need for AVR in Mild Aortic Stenosis
Investigators examined whether pretreatment low-density lipoprotein cholesterol levels and aortic stenosis severity affect lipid-lowering therapy to decrease aortic valve replacement.
Fluoroquinolone Exposure Linked to Increased Left-Sided Valvular Regurgitation Risk
Fluoroquinolone antibiotic exposure was linked to an increased risk of developing left-sided valvular regurgitation.
Elevated Systolic Blood Pressure May Increase Risk for Valvular Heart Disease
Blood pressure lowering might be a useful strategy for prevention of major valvular heart disease.
Lp(a), Oxidized Phospholipids Drive Valve Calcification in Aortic Stenosis
Investigators sought to determine whether lipoprotein(a) and oxidized phospholipids on apolipoprotein B-100 levels can affect disease activity, disease progression, and clinical events in patients with aortic stenosis.
Early AVR Associated With Improved Survival in Severe Asymptomatic Aortic Stenosis
Early aortic valve replacement (AVR) may improve survival in patients with severe, asymptomatic aortic stenosis.
PV Stenosis May Predict Mortality in Bronchopulmonary Dysplasia and PH
The severity of lung disease in preterm infants with bronchopulmonary dysplasia and pulmonary hypertension undergoing cardiac catheterization did not correlate with mortality.
MitraClip Device Approved for Patients With Secondary Mitral Regurgitation
Data show 47 percent reduction in risk for rehospitalization for HF symptoms with device implantation
Linear Association Between Plasma Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression
Lipoprotein(a) levels should be measured in mild to moderate calcific aortic valve stenosis to improve patient risk stratification.
Want to read more?
Please login or register first to view this content.